Sanders Capital’s AstraZeneca AZN Stock Holding History

Sanders Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.32B	Sell	6,986,830 -78,798	-1%	-$14.8M	1.33%	23
2026 Q1	$1.39B	Sell	7,065,628 -4,076	-0.1%	-$786K	1.66%	21
2025 Q4	$1.3B	Buy	7,069,704 +40,363	+0.6%	+$7.08M	1.5%	22
2025 Q3	$1.08B	Sell	7,029,341 -234,090	-3%	-$35.4M	1.33%	23
2025 Q2	$1.02B	Sell	7,263,431 -271,062	-4%	-$38M	1.36%	23
2025 Q1	$1.11B	Sell	7,534,493 -58,853	-0.8%	-$8.51M	1.66%	21
2024 Q4	$995M	Buy	7,593,346 +106,150	+1%	+$14.9M	1.45%	19
2024 Q3	$1.17B	Buy	7,487,196 +14,575	+0.2%	+$2.35M	1.69%	21
2024 Q2	$1.17B	Buy	7,472,621 +63,129	+0.9%	+$9.5M	1.79%	18
2024 Q1	$1B	Buy	7,409,492 +67,459	+0.9%	+$8.93M	1.68%	23
2023 Q4	$989M	Buy	7,342,033 +2,061,482	+39%	+$268M	1.83%	21
2023 Q3	$715M	Buy	+5,280,551	New	+$721M	1.51%	26

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sanders Capital's AZN Position: Q2 2026 in Review

Sanders Capital reduced its AstraZeneca (AZN) stake by 1.1% in Q2 2026, selling an estimated $14.8M and leaving 6,986,830 shares worth $1.32B. The position accounts for 1.33% of the portfolio, ranked #23.

Sanders Capital first reported a position in AZN in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.39B in Q1 2026. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Sanders Capital held 6,986,830 shares of AstraZeneca worth $1.32B as of Q2 2026.
Sanders Capital sold 78,798 AstraZeneca shares in Q2 2026, an estimated $14.8M.
AstraZeneca made up 1.33% of Sanders Capital's portfolio in Q2 2026, its #23 holding.
Sanders Capital first reported a position in AstraZeneca in Q3 2023 and has held it in 12 quarters since.
Sanders Capital's AstraZeneca position peaked at $1.39B in Q1 2026.
1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Sanders Capital's 13F filing for Q2 2026, filed 10 Aug 2026.